Flawed ivermectin preprint highlights challenges of COVID drug studies

Sara Reardon

Nature, 2021, vol. 596, issue 7871, 173-174

Abstract: The study’s withdrawal from a preprint platform deals a blow to the anti-parasite drug’s chances as a COVID treatment, researchers say.

Keywords: Research data; SARS-CoV-2; Public health; Publishing (search for similar items in EconPapers)
Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-021-02081-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:596:y:2021:i:7871:d:10.1038_d41586-021-02081-w

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-021-02081-w

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().